Leena Gandhi

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Abstract 5393: Preclinical efficacy and safety profile of NPX125, a novel ADC targeting B7-H7.

  Cancer Research · 2026-04-03

• Efficacy of Neratinib-Based Therapy in ERBB2-Mutant Lung Adenocarcinomas: Findings From 2 International Phase 2 Studies

  Clinical Lung Cancer · 2025-10-04

• Enfortumab vedotin in patients with advanced non-small cell lung cancer after disease progression on platinum- and PD-1/PD-L1 inhibitor-containing regimens: Phase 2 international multicenter EV-202 study

  European Journal of Cancer · 2025-07-15 · 4 citations

• Abstract 3302: Comprehensive analysis of B7-H7/HHLA2 expression in pan-solid tumors and its potential significance in anti-tumor immunity

  Cancer Research · 2025-04-21

• Abstract 4354: Safety and tolerability of NPX372, a novel B7-H7:CD3 bispecific T cell engaging antibody

  Cancer Research · 2025-04-21

• Mapping MAGE-A4 expression in solid cancers for targeted therapies

  Frontiers in Oncology · 2025-03-13 · 1 citations

• Supplementary Figure S2 from First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced CancerPreprint

  2024-11-25

• Supplementary Figure S1 from First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced CancerPreprint

  2024-11-25

• Supplementary Table S1 from First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer

  2024-11-25

• Supplementary Table S2 from First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer

  2024-11-25

• Supplementary Legend from First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced CancerPreprint

  2024-11-25

• Data from First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced CancerPreprint

  2024-11-25

• Supplementary Data from First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced CancerPreprint

  2024-11-25

• 182 (PB170): Results from a phase 1/2, first-in-human, dose escalation and dose expansion study of an investigational anti-ADAM9 antibody-drug conjugate IMGC936 in patients with advanced solid tumors

  European Journal of Cancer · 2024-10-01 · 1 citations

• 1070TiP A phase Ia/Ib dose-escalation/expansion study of NPX887 in subjects with solid tumor malignancies known to express HHLA2/B7-H7

  Annals of Oncology · 2024-09-01